Frontiers in Anti-Cancer Drug Discovery

Volume: 1

Indexed in: Scopus, Book Citation Index, Science Edition (BKCI-S), Web of Science, BIOSIS Previews, Scopus, EMBASE, Chemical Abstracts, EBSCO, Ulrich's Periodicals.

“Frontiers in Anti-Cancer Drug Discovery” is an eBook series devoted to publishing the latest and the most important advances in Anti-Cancer drug design and discovery. Eminent scientists write ...
[view complete introduction]

US $
15

*(Excluding Mailing and Handling)



Prevention and Treatment of Regimen-Related Mucosal Toxicity

Pp. 588-600 (13)

DOI: 10.2174/978160805161811001010588

Author(s): Joanne M. Bowen

Abstract

Current standard treatments for cancer are associated with major doselimiting toxic effects on healthy tissue. The mucosal layers of the body are particularly sensitive to regimen-induced damage, with patients suffering many unpleasant and potentially life-threatening side-effects. In recent years, there has been an increase in the understanding of the pathobiology of regimen-related mucosal injury which has lead to a number of exciting inventions for its prevention and treatment being recently patented. Agents such as growth factors, cytokines, receptor agonists/antagonists and anti-inflammatory agents are among those in development in this emerging field. The complexity of mucosal injury poses a challenge for researchers, however, rational targeting of intervention strategies to critical mechanisms will lead to further progress.

Keywords:

Mucosal injury, mucositis, chemotherapy, radiotherapy, inflammation, apoptosis, growth factor, intestine, oral